Puma Biotechnology Inc at JPMorgan Healthcare Conference (Virtual) Transcript
All right. Good morning, everyone, from the virtual JPMorgan Healthcare Conference. My name is Cory Kasimov, and it's my pleasure to introduce our next company, Puma Biotechnology, and Chairman and CEO, Alan Auerbach. Please note there will not be a Q&A session following this presentation. So with that, Alan, thanks for being with us here today, and let me turn things over to you.
Great. Thank you very much, Cory. Are we moving to my slides now? So just a reminder, I'm going to be making forward-looking statements.
So on Slide 3, you can see our product pipeline with neratinib. As you can see, we have neratinib in many different indications, both marketed ones as well as ones in developments. In terms of marketed indications, the drug is approved in 2 indications, both in HER2-positive breast cancer. One is the extended adjuvant indication, where it's approved
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
